We are live on
!
Find out more
SFM
Sphera Funds Management Portfolio holdings
AUM
$630M
1-Year Est. Return
108.65%
This Fund
S&P 500
This Quarter
Est. Return
-11.26%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$800M
AUM Growth
-$414M
(-34%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-29.97%
Top 10 Holdings %
Top 10 Hldgs %
59.99%
Holding
111
New
25
Increased
21
Reduced
27
Closed
33
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$26.8M |
| 2 |
Merck
MRK
|
+$25.8M |
| 3 |
Pfizer
PFE
|
+$19.8M |
| 4 |
AbbVie
ABBV
|
+$14.1M |
| 5 |
Sarepta Therapeutics
SRPT
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$21.3M |
| 2 |
VRNT
Verint Systems
VRNT
|
+$16.1M |
| 3 |
Johnson & Johnson
JNJ
|
+$12.8M |
| 4 |
Viatris
VTRS
|
+$11.3M |
| 5 |
PTC Therapeutics
PTCT
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.88% |
| 2 | Technology | 4.53% |
| 3 | Consumer Discretionary | 1.29% |
| 4 | Communication Services | 0.33% |
| 5 | Financials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
WIX.com
WIX
$2.3B
| – | – |
-41,415
| Closed | -$5.07M |
|
|
SGEN
102
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-250,000
| Closed | -$28.6M |
|
|
HARP
103
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| – | – |
-38,403
| Closed | -$5.68M |
|
|
BLCM
104
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| – | – |
-40,000
| Closed | -$516K |
|
|
GWPH
105
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-77,000
| Closed | -$8.05M |
|
|
PRNB
106
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
| – | – |
-86,500
| Closed | -$4.74M |
|
|
FSCT
107
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
| – | – |
-137,021
| Closed | -$4.49M |
|
|
PTLA
108
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| – | – |
-317,000
| Closed | -$7.57M |
|
|
MLNX
109
DELISTED
Mellanox Technologies, Ltd.
MLNX
| – | – |
-8,452
| Closed | -$990K |
|
|
ARQL
110
DELISTED
Arqule Inc
ARQL
| – | – |
-297,227
| Closed | -$5.93M |
|
Similar funds
VIM
KCMH
FCFC
BI
PWW
TTSTC
SWP
EIM
Sphera Funds Management's Q1 2020 Portfolio in Review
As of Q1 2020, Sphera Funds Management held 111 positions worth $800M, down 34% from $1.21B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Sphera Funds Management withdrew a net $240M in Q1 2020, closing 33 positions and reducing 27 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $21.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 52% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Sphera Funds Management opened a new position in AstraZeneca worth $25.5M.
- Sphera Funds Management's largest Q1 2020 buy was AstraZeneca: 285,000 shares worth $25.5M.
- Sphera Funds Management added most to Merck in Q1 2020, an estimated $25.8M increase.
- Sphera Funds Management's biggest Q1 2020 reduction was Johnson & Johnson, cutting an estimated $12.8M.
- Sphera Funds Management fully exited BioMarin Pharmaceuticals in Q1 2020, selling an estimated $21.3M.
- Sphera Funds Management's ten largest holdings make up 60% of its $800M portfolio in Q1 2020.
- Sphera Funds Management opened 25 new positions and closed 33 in Q1 2020.
- Sphera Funds Management's portfolio value fell 34% quarter-over-quarter to $800M.
Based on Sphera Funds Management's 13F filing for Q1 2020, filed 14 May 2020.